If scientific societies want public relations firms with both healthcare expertise and global reach to help them promote their conferences, it’s going to be difficult to avoid firms that also have pharmaceutical industry clients. But that won’t stop skeptics—like the folks at Embargo Watch—asking questions about potential conflict, so it would behoove both the scientific societies and their PR firms to have good answers ready.